Matching articles for "Micafungin"
Isavuconazonium Sulfate (Cresemba) - A New Antifungal
The Medical Letter on Drugs and Therapeutics • March 14, 2016; (Issue 1490)
The FDA has approved isavuconazonium sulfate
(Cresemba – Astellas) for intravenous and oral treatment
of invasive aspergillosis and invasive mucormycosis
in adults. Isavuconazonium sulfate is a prodrug...
The FDA has approved isavuconazonium sulfate
(Cresemba – Astellas) for intravenous and oral treatment
of invasive aspergillosis and invasive mucormycosis
in adults. Isavuconazonium sulfate is a prodrug of
isavuconazole, a broad-spectrum triazole antifungal.
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • August 1, 2012; (Issue 120)
The drugs of choice for treatment of fungal infections
are listed in the table that begins on page 62. Some of
the indications and dosages recommended here have
not been approved by the FDA. More detailed...
The drugs of choice for treatment of fungal infections
are listed in the table that begins on page 62. Some of
the indications and dosages recommended here have
not been approved by the FDA. More detailed guidelines
for some of these infections are available online
from the Infectious Diseases Society of America
(www.idsociety.org).
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • December 1, 2009; (Issue 88)
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from...
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from the Infectious Diseases Society of America (www.idsociety.org).
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • January 1, 2008; (Issue 65)
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from...
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America (www.idsociety.org).
Anidulafungin (Eraxis) for Candida Infections
The Medical Letter on Drugs and Therapeutics • May 22, 2006; (Issue 1235)
Anidulafungin (ay nid yoo la fun jin; Eraxis - Pfizer), a third intravenous echinocandin antifungal, has been approved by the FDA for treatment of esophageal candidiasis, candidemia, and other complicated...
Anidulafungin (ay nid yoo la fun jin; Eraxis - Pfizer), a third intravenous echinocandin antifungal, has been approved by the FDA for treatment of esophageal candidiasis, candidemia, and other complicated Candida infections (intra-abdominal abscess or peritonitis).
Micafungin (Mycamine) for Fungal Infections
The Medical Letter on Drugs and Therapeutics • June 20, 2005; (Issue 1211)
Micafungin sodium (Mycamine - Astellas), the second echinocandin antifungal to become available in the US, has been approved by the FDA for intravenous treatment of esophageal candidiasis and prophylaxis of...
Micafungin sodium (Mycamine - Astellas), the second echinocandin antifungal to become available in the US, has been approved by the FDA for intravenous treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT).
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • February 1, 2005; (Issue 30)
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the...
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.